Table 3.

Pathological complete response (pCR) rates after 3 to 12 months of NET.

NET	pCR %
P024 [10]	1.5
Allevi [28]
4 months	2.5
8 months	5
12 months	17.5
Semiglazov 2007 [24]	3
GEICAM 2006-03 [23]	0
NEOCENT [26]	0
ACOSOG Z1031 [14]	1.6
NeoPAL 1 [45]	3.8
CORALLEEN 2 [46]	0

^1,2 Patients included in NeoPAL ¹ and CORALLEEN trials ² who were randomized to receive ET also received palbociclib or ribociclib, respectively.